LONDON: Oxford Biomedica plc, a leading cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has released its preliminary financial results for the year ending December 31, 2023. Despite a challenging year, the Group has maintained stable core business revenues with a slight increase, although total revenues saw a significant drop of 36% to…
LONDON, UK: Oxford Biomedica, a leading cell and gene therapy CDMO, has announced a business update for the year ending 31 December 2023. The update highlights the Company’s progress in transforming its operations, expanding its client base, and enhancing its capabilities across multiple viral vector platforms and sites. The Company has completed the reorganisation of…
LONDON, UK: Oxford Biomedica has entered into an agreement with Homology Medicines Inc. to acquire an 80 per cent ownership interest in a newly formed AAV focused manufacturing and innovation business, Oxford Biomedica Solutions LLC or Oxford Biomedica Solutions’ AAV Manufacturing and Innovation Business, at an implied pre-money enterprise value of approximately $175 million. Oxford…
OXFORD: Oxford Biomedica has signed a new three year Development & Supply Agreement (DSA) with Boehringer Ingelheim for the manufacture and supply of various types of viral vectors. Under the terms of the DSA, Oxford Biomedica intends to manufacture GMP batches for Boehringer Ingelheim to support the development of viral vectors. The DSA also allows…
OXFORD: Oxford Biomedica has signed a Collaboration Agreement with the Vaccines Manufacturing and Innovation Centre (VMIC), a not-for-profit organisation established to provide the UK’s first strategic vaccine development and advanced manufacturing capability. This five year Agreement will involve the organisations working collaboratively to enable the manufacture of viral vector based vaccines, contributing towards a rapid…
OXFORD: Oxford Biomedica plc has announced the successful outcome of their recent UK Medicines & Healthcare products Regulatory Agency (MHRA) inspection, resulting in the issue of a Certificate of GMP compliance for the first two GMP manufacturing suites and supporting area such as warehouse, cold chain facilities and QC laboratories, in its new Oxbox manufacturing…